DB05771Experimental
The botanical drug product LLL-3348 is a once-daily oral formulation for treatment of chronic stable plaque type psoriasis.
- Mechanism
- Curator reviewed
LLL-3348 acts by enhancing IL-10.
- Primary indication
- Investigated for use/treatment in psoriasis and psoriatic disorders.Curator reviewed
- Code names
- LLL-3348
Resolves to
Targets
What you can answer from here — as of March 06, 2025
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with LLL-3348, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account